|
|
|
|
Дата |
|---|
| 22:26 |
| 23.06.2026 |
| 22.06.2026 |
| 18.06.2026 |
| 17.06.2026 |
| 16.06.2026 |
| 15.06.2026 |
| 12.06.2026 |
| 11.06.2026 |
| 10.06.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
4.90
|
4.97
|
4.28
|
4.28
|
5.13
|
4.93
|
|
|
119 597.29
|
367.00
|
|
4.13
|
4.63
|
4.05
|
4.025
|
4.44
|
4.225
|
|
|
39 538.56
|
185.00
|
|
4.08
|
4.18
|
3.96
|
3.96
|
4.095
|
4.08
|
|
|
25 779.03
|
166.00
|
|
3.66
|
4.04
|
3.88
|
3.71
|
3.98
|
3.91
|
|
|
54 238.15
|
215.00
|
|
3.70
|
4.00
|
3.77
|
3.72
|
3.94
|
3.80
|
|
|
22 991.17
|
145.00
|
|
3.72
|
4.11
|
3.88
|
3.72
|
3.90
|
3.72
|
|
|
30 383.74
|
166.00
|
|
3.65
|
4.33
|
3.98
|
3.81
|
4.10
|
3.855
|
|
|
69 906.31
|
265.00
|
|
3.78
|
4.00
|
3.64
|
3.64
|
3.91
|
3.905
|
|
|
29 881.48
|
122.00
|
|
3.31
|
4.44
|
3.64
|
3.45
|
3.653
|
3.653
|
|
|
20 298.07
|
157.00
|
|
3.37
|
4.48
|
3.56
|
3.48
|
3.68
|
3.48
|
|
|
44 621.79
|
195.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть